⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6504654 | 0.81 | — | — | |
| SCHEMBL3504904 | 0.77 | — | — | |
| SCHEMBL22912549 | 0.76 | CNR2 (0.32) | — | |
| SCHEMBL25271760 | 0.76 | — | — | |
| SCHEMBL10480738 | 0.75 | — | — | |
| SCHEMBL2238130 | 0.75 | — | — | |
| SCHEMBL2616804 | 0.75 | TLR8 (0.33) | — | |
| SCHEMBL13566370 | 0.73 | — | — | |
| SCHEMBL13765710 | 0.73 | GAA (0.39) | — | |
| SCHEMBL13799704 | 0.73 | KDM4E (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552799-B2 | Triazolone compounds | NXERA PHARMA UK LIMITED (GB) | 2026-02-17 | — | — | US | disclosed |
| CN-115867550-B | Triazolone compounds | 奈克斯拉制药英国有限公司 | 2025-01-03 | — | — | CN | disclosed |
| EP-4126871-B1 | TRIAZOLONE COMPOUNDS | HEPTARES THERAPEUTICS LTD (GB) | 2024-05-08 | — | — | EP | disclosed |
| US-20240066027-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2024-02-29 | — | — | US | disclosed |
| EP-4255904-A2 | NOVEL PAR-2 INHIBITORS | Domain Therapeutics (FR) | 2023-10-11 | — | — | EP | disclosed |
| US-20230271964-A1 | 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER | NXERA PHARMA UK LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-20230146796-A1 | TRIAZOLONE COMPOUNDS | ASTRAZENECA AB (SE) | 2023-05-11 | — | — | US | disclosed |
| US-20230146796-A1 | TRIAZOLONE COMPOUNDS | ASTRAZENECA AB (SE) | 2023-05-11 | — | — | US | disclosed |
| US-20230146796-A1 | TRIAZOLONE COMPOUNDS | ASTRAZENECA AB (SE) | 2023-05-11 | — | — | US | disclosed |
| CN-115867550-A | Triazolone compounds | 赫普泰雅治疗有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-7179823-B1 | 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-20 | — | — | US | disclosed |
| US-20070027173-A1 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-01 | — | — | US | disclosed |
| WO-2007006688-A1 | INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006034296-A2 | AMINO-CONTAINING COMPOUNDS WHICH INHIBIT MEMAPSIN 2 BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| EP-1457490-A1 | 5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity | Takeda Chemical Industries, Ltd. (JP) | 2004-09-15 | — | — | EP | disclosed |
| EP-1228067-B1 | 5-MEMBERED N-HETEROCYCLIC COMPOUNDS WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-07-14 | — | — | EP | disclosed |
| EP-0539421-B1 | NOVEL OXAZOLYL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 1998-09-23 | — | — | EP | disclosed |
| US-5278165-A | Oxazolyl imidazol[4,5-b]pyridin and pyrimidine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-01-11 | — | — | US | disclosed |
| US-5217980-A | Antiallergens | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-06-08 | — | — | US | disclosed |
| WO-1992001687-A1 | NOVEL OXAZOLYL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-02-06 | — | — | WO | disclosed |